https://en.bioecon.ru/companies/beigene/Recent content in Beigene on BioeconHugoen-USWed, 29 Jul 2026 09:52:30 +0700https://en.bioecon.ru/technology/bispecific-antibodies/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/bispecific-antibodies/Engineered antibodies that bind two (or more) antigens on one molecule — most powerfully a CD3 arm that recruits the patient’s own T cells to a tumour cell — delivered off-the-shelf as approved drugs across lymphoma and myeloma by Roche, Janssen, Regeneron, AbbVie/Genmab and BeiGene.https://en.bioecon.ru/technology/protacs/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/protacs/Bifunctional small molecules that recruit an E3 ubiquitin ligase to a disease protein, tagging it for proteasomal destruction — an event-driven, catalytic drug modality approaching its first approval with Arvinas’s estrogen-receptor degrader vepdegestrant, and a deep pipeline across IRAK4, IKZF and BTK targets.https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/Large-molecule therapeutics manufactured via living cells to treat complex diseases like cancer, diabetes, and autoimmune disorders.